Levetiracetam "Stada" 100 mg/ml oral opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

levetiracetam "stada" 100 mg/ml oral opløsning

stada arzneimittel ag - levetiracetam - oral opløsning - 100 mg/ml

Leviprim 100 mg/ml oral opl?sning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

leviprim 100 mg/ml oral opl?sning

nordic prime aps - levetiracetam - oral opløsning - 100 mg/ml

Duavive Den Europæiske Union - dansk - EMA (European Medicines Agency)

duavive

pfizer europe ma eeig - østrogener konjugeret, bazedoxifene - menopausen - konjugerede østrogener og bazedoxifene - duavive er indiceret til:behandling af østrogen mangel symptomer hos postmenopausale kvinder med uterus (med mindst 12 måneder siden sidste menstruation), for hvem behandling med gestagen, der indeholder terapi er ikke passende. den erfaring med behandling af kvinder over 65 år er begrænset.

Phenergan 1 mg/ml oral opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

phenergan 1 mg/ml oral opløsning

paranova danmark a/s - promethazinhydrochlorid - oral opløsning - 1 mg/ml

Imatinib Koanaa Den Europæiske Union - dansk - EMA (European Medicines Agency)

imatinib koanaa

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastiske midler - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patienter, der har en lav eller meget lav risiko for tilbagefald, bør ikke modtage adjuverende behandling. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. undtagen i nyligt diagnosticeret kronisk cml-fase, der er ingen kontrollerede undersøgelser, der påviser en klinisk fordel eller øget overlevelse for disse sygdomme.

Levetiracetam Accord Healthcare 100 mg/ml oral opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

levetiracetam accord healthcare 100 mg/ml oral opløsning

2care4 aps - levetiracetam - oral opløsning - 100 mg/ml

Dovato Den Europæiske Union - dansk - EMA (European Medicines Agency)

dovato

viiv healthcare b.v. - dolutegravir natrium, lamivudin - hiv infektioner - antivirale midler til systemisk anvendelse - dovato er indiceret til behandling af human immundefekt virus type 1 (hiv-1) infektion hos voksne og unge over 12 år, som vejer mindst 40 kg, og som er uden kendt eller formodet resistens over for integrase inhibitor klasse, eller lamivudin.

Phenergan 1 mg/ml oral opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

phenergan 1 mg/ml oral opløsning

opella healthcare france sas - promethazinhydrochlorid - oral opløsning - 1 mg/ml

Phenergan 1 mg/ml oral opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

phenergan 1 mg/ml oral opløsning

orifarm a/s - promethazinhydrochlorid - oral opløsning - 1 mg/ml

Retrovir 10 mg/ml oral opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

retrovir 10 mg/ml oral opløsning

viiv healthcare bv - zidovudin - oral opløsning - 10 mg/ml